Márk Harmat

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

Krisztina Horváth, Zsuzsanna Aschermann, Márton Kovács et al. · Neuroepidemiology · 2017 · 168 citations

Medicine, Neurology, Neuroscience +16

Minimal clinically important differences for the experiences of daily living parts of movement disorder society–sponsored unified Parkinson's disease rating scale

Krisztina Horváth, Zsuzsanna Aschermann, Márton Kovács et al. · Movement Disorders · 2017 · 110 citations

Medicine, Neurology, Functional Movement Assessment +12

Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open-label study

Annamária Juhász, Zsuzsanna Aschermann, Péter Ács et al. · Parkinsonism & Related Disorders · 2017 · 46 citations · Full text

Medicine, Neurology, Neuroscience +16

Are the MDS‐UPDRS–Based Composite Scores Clinically Applicable?

Attila Makkos, Márton Kovács, Zsuzsanna Aschermann et al. · Movement Disorders · 2018 · 36 citations

Medicine, Neurology, Movement Analysis +15

Antiparkinsonian Drug Reduction After Directional Versus Omnidirectional Bilateral Subthalamic Deep Brain Stimulation

Dávid Pintér, Evelyn Járdaházi, István Balás et al. · Neuromodulation Technology at the Neural Interface · 2022 · 22 citations · Full text

Medicine, Neurology, Pharmacotherapy +17